Skip to content
Thursday, March 13, 2025
GLP-1 Watch
All the latest news and updates about GLP-1 Drugs
Search
Search
Privacy Policy
The Evolving Landscape of GLP-1 Drugs: Innovations, Market Trends, and Health Implications
Home
2025
March
3
EC approves Bavarian Nordic’s chikungunya vaccine marketing
GLP-1 News
EC approves Bavarian Nordic’s chikungunya vaccine marketing
March 3, 2025
admin
The EC has authorised the marketing of Bavarian Nordic’s Vimkunya chikungunya vaccine for individuals as young as 12 years old.
Post navigation
Ryoncil, the first FDA-approved mesenchymal stromal cell therapy
Faced with compounded drugs, Eli Lilly tells consumers to ‘be a healthy skeptic’ – Campaign in Canada